期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

放疗联合厄洛替尼治疗非小细胞肺癌的临床研究 被引量：4

下载PDF
导出
摘要 目的观察放疗联合厄洛替尼治疗晚期非小细胞肺癌的近期疗效及临床获益效果。方法 40例晚期非小细胞肺癌患者均有组织病理学或细胞学诊断及可评价的客观指标。20例(联合组)采用厄洛替尼150mg/d口服治疗,同时给予同步放射治疗,常规放射治疗6000cGY/30d。20例(放疗组)采用单纯放射治疗,常规放射治疗6000cGY/30d。结果 40例全部完成治疗,联合组完全缓解(CR)4例,部分缓解(PR)10例,总有效率(CR+PR)为70%,1年和3年生存率和中位生存期联合组分别为72%,38%和26.3个月。单纯放疗组CR1例,PR7例,总有效率(CR+PR)40%,1年和3年生存率和中位生存期分别为56%,22%和16.6个月。2组疗效差异有统计学意义(P<0.05)。结论放疗联合厄洛替尼是治疗晚期非小细胞肺癌患者的有效方案,能缓解症状,改善生活质量,延长生存期。
作者 梁献伟 张楠 李秀莉 马志乾 王敬然 张富同 安永辉
机构地区 河北省石家庄市第一医院
出处 《河北医药》 CAS 2010年第24期3474-3475,共2页 Hebei Medical Journal
关键词 放疗 厄洛替尼 晚期非小细胞肺癌
分类号 R730.55 [医药卫生—肿瘤] R979.1 [医药卫生—药品]
  • 相关文献

参考文献7

  • 1罗俊华,李娟.厄洛替尼治疗老年晚期NSCLC的临床观察[J].肿瘤防治研究,2009,36(3):244-246. 被引量：2
  • 2Toma-Dasu I,Dasu A,Karlsson M.The relationship between temporal variation of hypoxia,polarographic measurements and predictions of tumor response to radiation.Phys Med Biol,2004,49:4463-4475.
  • 3Fontanini G,De Laurentiis M,Vignati S,et al.Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stageⅠ-ⅢA non-small-cell lung cancer:amphiregulin and microvessel count are independent prognostic indicators of survival.Clin Cancer Res,1998,4:241-249.
  • 4Rusch V.Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in respectable non-small cell lung cancer but does not predict tumor progression.Clin Cancer Res,1997,3:515-522.
  • 5马艳杰,毛燕欣.盐酸厄洛替尼[J].中国新药杂志,2007,16(11):903-904. 被引量：15
  • 6De Jager J,Stebbing J.Erlotinib or capecitabine with gemcitabine in pancreatic cancer.FutureOncol,2006,2:161-163.
  • 7Lynch T Jr,Kim E.Optimizing chemotherapy and targeted agent combinations in NSCLC.Lung Cancer,2005,50:S25-32.

二级参考文献12

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量：1480
  • 2邓湘,修霞,谭爱国.CYFRA21-1和CEA对Ⅲ期非小细胞肺癌患者的临床预后意义[J].中国实验诊断学,2007,11(6):779-781. 被引量：4
  • 3Shepherd FA,Pereira J,Ciuleanu TE, et al. A randomized placebo-controlled trial or erlotinib in patients with advanced non- small lung eancer(NSCLC) following failure of 1^st line or 2^nd line chemotherapy. A National Cancer Institue of Canada Clinical Trials Group. (NCIC CTG) trial. Promgram and abstracts of the 40^th Annual Meeting of the American Society of Clinical Oncology,June 5-8,2004[C]. New Orleans, LA, 7022.
  • 4Grunwald V, Hidalgo M. Developing inhibitors of the ep iderreal growth factor receptor for cancer treatment [ J ]. J Natl Cancer Inst, 2003, 95(8): 851-867.
  • 5Shepherd FA, Rodrigues J, Ciuleanu T, et al. Erlotinib in previ-ously treated non-small cell lung cancer [ J ]. N Engl J Med,2005, 353(5) : 123-132.
  • 6Bezjak A, Shepherd F, Tu D, et al. Symptom response in non-small cell lung cancer (NSCLC) patients treated with erlotinib:Quality of life analysis of the NCIC CTG BR. 21 trial [J]. Pro Am Soc Clin Oncol,2005,23:635(Abstr 7018).
  • 7Maione P, Gridelli C, Troiani T, et al. Combining trgeted therapies and drugs with multiple targets in the treatment of NSCLC [ J ]. Oncologist, 2006,11 (3):274-284.
  • 8Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-faetor reeeptors a review of clinical research with a focuson non-small cell lung cancer[J]. Lancet Oncol, 2003, 4(9) : 397-406.
  • 9陆舜,李子明,成柏君,虞永峰,廖美琳,叶云.厄洛替尼治疗复治晚期非小细胞肺癌的临床分析[J].中国癌症杂志,2007,17(9):711-715. 被引量：46
  • 10SHEPHERD FA,PEREIRA JR,CIULEANU T,et al.Erlotinib in Previously Treated Non-Small-Cell Lung Cancer[J].N Engl J Med,2005,353(2):123-132

共引文献15

同被引文献79

  • 1余奇,郭澄.酪氨酸激酶抑制剂厄洛替尼的研究进展[J].药学服务与研究,2010,10(6):453-457. 被引量：5
  • 2蔡俊明,丘昭华,刘家伶,蔡佩君,彭瑞鹏.吉非替尼(Gefitinib)对非小细胞肺癌的脑部转移具有疗效[J].中国肺癌杂志,2004,7(4):298-304. 被引量：20
  • 3王燕,王颖,王彬,王子平,张湘茹,储大同,孙燕.吉非替尼治疗非小细胞肺癌脑转移的初步结果[J].中国肺癌杂志,2006,9(5):447-451. 被引量：33
  • 4张力.分子靶向治疗非小细胞肺癌最新汇瘁.临床肿瘤学进展,2010,.
  • 5Villano JL,Maucer AM,Vokes EE. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain [ J ]. Ann On- col ,2003,14:656 - 658.
  • 6Wang M, Jing Z, Minjiang C. Cerebral penetration of gefitinib in patients with lung adenocarcinoma [ J ]. J Clin Oncol, 2011,29 (Suppl) : a7608.
  • 7Jackman DM, Holmes AJ, Lindeman N, et al. Response and re- sistance in a non-small cell lung cancer patient with an epidermal 4517 factor receptor mutation and leptomeningeal metastases with high-dose gefitinib [ J ]. J Clin Oncol,2006,24 ( 27 ) : 4520.
  • 8Heimberger AB, Learn CA, Archer GE, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839(Iressa) [ J]. Clin Cancer Res, 2002, 8 ( 11 ) : 3496 - 3502.
  • 9Kim JE, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis [ J ]. Lung Cancer, 2009,65 ( 3 ) : 351 - 354.
  • 10Wu YL, Zhou C, Cheng Y, et al. A phase Ⅱ study ( CTONG0803 ) of erlotinib as second-line treatment in advanced non-small cell lung cancer patients with asymptomatic brain metastases after first- line chemotherapy [ J ]. J Clin Oncol, 2011,29 (Suppl) : a7605.

引证文献4

二级引证文献9

河北医药
2010年 第24期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部